Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A—results of pathfinder (TM) 2 international trial - Giangrande, P; Chowdary, P; Enhrenforth, S (J Thromb Haemost, 2015)
, et al.